Lupin
Drug Manufacturers - Specialty & Generic · LUPIN
Mega CapHealthcareMature Stable
Nilesh Gupta
Managing Director · Pragmatic
Company DNA
Hierarchical
About
Lupin is a Mega Cap company in the Healthcare sector, listed on NSE as LUPIN. With a market cap of ₹105K Cr and revenue of ₹22K Cr, it is currently in the Mature Stable phase. Known for its Hierarchical culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Long-standing family-promoted pharmaceutical business with a structured, traditional management hierarchy. Its strategic mandate: Recovery efforts necessitate a streamlined cost structure and improved manufacturing compliance to navigate complex global regulatory requirements.
FAQ
What kind of company is Lupin?
Lupin is a Mega Cap Healthcare company (LUPIN) in the Mature Stable phase with a market cap of ₹105K Cr. It is classified as Hierarchical in culture.
What is Lupin's culture and work environment like?
Lupin has a Hierarchical culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Long-standing family-promoted pharmaceutical business with a structured, traditional management hierarchy.
Who leads Lupin?
Lupin is led by Nilesh Gupta (Managing Director), a Pragmatic leader with 23 years of experience.
What are Lupin's financials?
Lupin reported revenue of ₹22K Cr in FY25 with a 5-year revenue CAGR of 11.1%. Operating margin: 19.6%. Market cap: ₹105K Cr.
Culture & Strategy
CultureHierarchical
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTrusted
LifecycleMature Stable
Long-standing family-promoted pharmaceutical business with a structured, traditional management hierarchy.
Mandate
Recovery efforts necessitate a streamlined cost structure and improved manufacturing compliance to navigate complex global regulatory requirements.
Recovery efforts necessitate a streamlined cost structure and improved manufacturing compliance to navigate complex global regulatory requirements.
Financials
Revenue FY25₹22K Cr
PAT FY25₹3K Cr
Rev CAGR 5Y11.1%
OPM19.6%
NPM14.8%
ROE19.1%
ROCE21.5%
P/E22.8
Fwd P/E23.7
P/B5.4
D/E31.5
Mkt Cap₹105K Cr
Promoter47%
Institutional32.9%
Similar Culture
Could You Lead Lupin?
Take the Genome Benchmark →